0
Catégories
Documents disponibles dans cette catégorie (8)
Ajouter le résultat dans votre panier Affiner la rechercheAssociation between cannabis use and symptom dimensions in schizophrenia spectrum disorders / Mathilde Argote (2023)
Titre : Association between cannabis use and symptom dimensions in schizophrenia spectrum disorders : an individual participant data meta-analysis on 3053 individuals Type de document : document électronique Auteurs : Mathilde Argote, Auteur ; Guillaume Sescousse, Auteur ; Jérôme Brunelin, Auteur Editeur : Lancet Année de publication : 2023 Collection : The Lancet num. 64 Importance : 13 p. Présentation : graph.,tab. Langues : Anglais (eng) Catégories : [TABAC] tabagisme:pathologie:pathologie neurologique:schizophrénie
[TABAC] tabagisme:risque:facteur associé:drogue:cannabisMots-clés : revue de la littérature Index. décimale : TA 1.1.5 Cannabis Résumé : Background
The association between cannabis use and positive symptoms in schizophrenia spectrum disorders is well documented, especially via meta-analyses. Yet, findings are inconsistent regarding negative symptoms, while other dimensions such as disorganization, depression, and excitement, have not been investigated. In addition, meta-analyses use aggregated data discarding important confounding variables which is a source of bias.
Methods
PubMed, ScienceDirect and PsycINFO were used to search for publications from inception to September 27, 2022. We contacted the authors of relevant studies to extract raw datasets and perform an Individual Participant Data meta-analysis (IPDMA). Inclusion criteria were: psychopathology of individuals with schizophrenia spectrum disorders assessed by the Positive and Negative Syndrome Scale (PANSS); cannabis-users had to either have a diagnosis of cannabis use disorder or use cannabis at least twice a week. The main outcomes were the PANSS subscores extracted via the 3-factor (positive, negative and general) and 5-factor (positive, negative, disorganization, depression, excitement) structures. Preregistration is accessible via Prospero: ID CRD42022329172.
Findings
Among the 1149 identified studies, 65 were eligible and 21 datasets were shared, totaling 3677 IPD and 3053 complete cases. The adjusted multivariate analysis revealed that relative to non-use, cannabis use was associated with higher severity of positive dimension (3-factor: Adjusted Mean Difference, aMD = 0.34, 95% Confidence Interval, CI = [0.03; 0.66]; 5-factor: aMD = 0.38, 95% CI = [0.08; 0.63]), lower severity of negative dimension (3-factor: aMD = −0.49, 95% CI [−0.90; −0.09]; 5-factor: aMD = −0.50, 95% CI = [−0.91; −0.08]), higher severity of excitement dimension (aMD = 0.16, 95% CI = [0.03; 0.28]). No association was found between cannabis use and disorganization (aMD = −0.13, 95% CI = [−0.42; 0.17]) or depression (aMD = −0.14, 95% CI = [−0.34; 0.06]).
Interpretation No causal relationship can be inferred from the current results. The findings could be in favor of both a detrimental and beneficial effect of cannabis on positive and negative symptoms, respectively. Longitudinal designs are needed to understand the role of cannabis is this association. The reported effect sizes are small and CIs are wide, the interpretation of findings should be taken with caution.
Funding
This research did not receive any specific grant or funding. Primary financial support for authors was provided by Le Vinatier Psychiatric Hospital.En ligne : https://doi.org/10.1016/j.eclinm.2023.102199 Format de la ressource électronique : Article en ligne Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=10275 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Titre : Le cannabis qui rend fou Type de document : texte imprimé Auteurs : J. S., Auteur Editeur : Ed. du Médecin Généraliste (EMG) Année de publication : 09/08/2007 Collection : Le Généraliste num. 839 Importance : p.11 Langues : Français (fre) Catégories : [TABAC] étude
[TABAC] tabagisme:pathologie:pathologie neurologique:schizophrénie
[TABAC] tabagisme:risque:facteur associé:drogue:cannabisIndex. décimale : TA 1.1 Tabac fumé Résumé : De nouvelles recherches confirment le lien entre consommation de cannabis et apparition d'une schizophrénie. Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=2658 Exemplaires (1)
Code-barres Cote Support Localisation Section Disponibilité TA 001540 TA 1.1 JSX C Article/Périodique Bibliothèque FARES Tabac Consultation sur place
Exclu du prêtAucun avis, veuillez vous identifier pour ajouter le vôtre !
Interventions for smoking cessation and reduction in individuals with schizophrenia / DT Tsoi (2013)
Titre : Interventions for smoking cessation and reduction in individuals with schizophrenia Type de document : texte imprimé Auteurs : DT Tsoi, Auteur ; M. Porwal, Auteur ; AC Webster, Auteur Editeur : The Cochrane Collaboration Année de publication : 2013 Collection : Cochrane Database of Systematic Reviews num. 28(2) Importance : 29 p. Langues : Français (fre) Catégories : [TABAC] sevrage tabagique
[TABAC] tabagisme:pathologie:pathologie neurologique:schizophrénieIndex. décimale : TA 2.4 Épidémiologie spécifique Résumé : Conclusion :
Bupropion increases smoking abstinence rates in smokers with schizophrenia, without jeopardizing their mental state. Varenicline may also improve smoking cessation rates in schizophrenia, but its possible psychiatric adverse effects cannot be ruled out. CR may help this group of patients to quit and reduce smoking in the short term. We failed to find convincing evidence that other interventions have a beneficial effect on smoking in schizophrenia.En ligne : http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007253.pub3/abstract Format de la ressource électronique : Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=7993 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Titre : A randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of varenicline for smoking cessation in patients with schizophrenia or schizoaffective disorder Type de document : texte imprimé Auteurs : Jill M. William, Auteur ; Robert M. Anthenelli, Auteur ; Chad Morris, Auteur ; Joan Treadow, Auteur Editeur : Physicians Postgraduate Press Année de publication : 2012 Collection : The Journal of clinical psychiatry, ISSN 0160-6689 num. 73:5 Importance : p. 654-660 Présentation : tab. Langues : Anglais (eng) Catégories : [TABAC] étude
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:varénicline
[TABAC] tabagisme:pathologie:pathologie neurologique:schizophrénieIndex. décimale : TA 6.2.3.2 Autres produits Résumé : OBJECTIVE:
Effective smoking cessation treatments are needed for patients with schizophrenia, who, compared with the general population, have high rates of cigarette smoking and more difficulty quitting. We evaluated the safety and efficacy of varenicline for smoking cessation in outpatients with stable schizophrenia or schizoaffective disorder.
METHOD:
In this 12-week, randomized, double-blind, multicenter trial (May 8, 2008, to April 1, 2010), 127 smokers (≥ 15 cigarettes/d) with DSM-IV-confirmed schizophrenia or schizoaffective disorder received varenicline or placebo (2:1 ratio). The primary outcome was safety and tolerability of varenicline assessed by adverse events frequency and changes in ratings on the Positive and Negative Syndrome Scale and other psychiatric scales from baseline to 24 weeks. Abstinence was defined as no smoking 7 days prior to weeks 12 and 24, verified by carbon monoxide level.
RESULTS:
Eighty-four participants received varenicline; 43, placebo. At 12 weeks (end of treatment), 16/84 varenicline-treated patients (19.0%) met smoking cessation criteria versus 2/43 (4.7%) for placebo (P = .046). At 24 weeks, 10/84 (11.9%) varenicline-treated and 1/43 (2.3%) placebo-treated patients, respectively, met abstinence criteria (P = .090). Total adverse event rates were similar between groups, with no significant changes in symptoms of schizophrenia or in mood and anxiety ratings. Rates of suicidal ideation adverse events were 6.0% (varenicline) and 7.0% (placebo) (P = 1.0). There was 1 suicide attempt by a varenicline patient with a lifetime history of similar attempts and no completed suicides.
CONCLUSIONS:
Varenicline was well tolerated, with no evidence of exacerbation of symptoms, and was associated with significantly higher smoking cessation rates versus placebo at 12 weeks. Our findings suggest varenicline is a suitable smoking cessation therapy for patients with schizophrenia or schizoaffective disorder.Note de contenu : Reprint with correction to page 658 Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=8093 Exemplaires (1)
Code-barres Cote Support Localisation Section Disponibilité TA 005642 TA 6.2.3.2 WIL R Article/Périodique Bibliothèque FARES Tabac Consultation sur place
Exclu du prêtAucun avis, veuillez vous identifier pour ajouter le vôtre !
Titre : A review of varenicline's efficacy and tolerability in smoking cessation studies in subjects with schizophrenia Type de document : texte imprimé Auteurs : Mahatab, Karkhane Yousefi, Auteur ; Thimothy D. Folsom, Auteur ; S. Hossein Fatemi, Auteur Editeur : Sunnyvale (CA) [Etats-Unis] : OMICS Pub. Group Année de publication : 2012 Collection : Journal of addiction research & therapy, ISSN 2155-6105 Importance : 14 p. Présentation : tab. Langues : Anglais (eng) Catégories : [TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:bupropion
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:varénicline
[TABAC] tabagisme:pathologie:pathologie neurologique:schizophrénieIndex. décimale : TA 6.2.3.2 Autres produits Résumé : chizophrenia is a severe psychiatric disorder affecting 1% of the world’s population. Nicotine addiction is one of the most important health concerns for patients with schizophrenia. An extensive body of evidence points to a high prevalence rate of comorbid nicotine addiction in people with schizophrenia (70–90%), which contributes to significant cardiovascular and cancer risks in this vulnerable population. Therefore, effective smoking cessation strategies could play a major role in preventing significant morbidity and mortality in this population. Two of the most common pharmacological approaches to smoking cessation, bupropion and nicotine replacement therapy (NRT), have been used in psychiatric patients to reduce their smoking. In 2006, varenicline, a partial agonist of α4β2 acetylcholine receptor, was approved for smoking cessation by the FDA. This drug not only has the beneficial effects on withdrawal symptoms, but also reduces craving and rewarding effects of smoking. While varenicline has been shown to be an effective, safe medication for the general population, its efficacy and safety for subjects with schizophrenia is less well characterized. A number of case studies have prompted FDA warnings about the potential exacerbation of psychiatric symptoms. However, other case studies and pilot studies have shown varenicline to be a safe and effective treatment for smoking cessation in subjects with schizophrenia. Varenicline has the potential to reduce smoking in subjects with schizophrenia, however, clinicians should carefully monitor patients receiving varenicline for potential exacerbation of psychiatric symptoms. En ligne : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3327361/ Format de la ressource électronique : HTML Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=8050 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
Titre : Smoking cessation in psychiatry : is there sufficient evidence to recommend smoking cessation activities? - a review of litterature Type de document : texte imprimé Auteurs : Charlotta Pisinger, Auteur Editeur : Network of Health Promoting Hospitals in Denmark Année de publication : 2007 Importance : 23 p. Langues : Anglais (eng) Catégories : [TABAC] sevrage tabagique:méthode de sevrage:méthode collective:groupe
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:bupropion
[TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:substitution nicotinique
[TABAC] tabagisme:effet du tabac:effet psychiatrique:dépression
[TABAC] tabagisme:pathologie:pathologie neurologique:schizophrénie
[TABAC] tabagisme:risque:facteur associé:alcoolIndex. décimale : TA 6.1 Généralités Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=8096 Exemplaires (1)
Code-barres Cote Support Localisation Section Disponibilité TA 005645 TA 6.1 PIS S Article/Périodique Bibliothèque FARES Tabac Consultation sur place
Exclu du prêtAucun avis, veuillez vous identifier pour ajouter le vôtre !
Titre : Tabac et schizophrénie Type de document : texte imprimé Auteurs : Aad Bosmans, Auteur Editeur : Ixelles [Belgique] : Fonds des Affections Respiratoires (FARES) asbl Année de publication : 2004 Importance : 17 p. Note générale : biblio. Langues : Français (fre) Catégories : [TABAC] étude:statistique:mortalité
[TABAC] prévention
[TABAC] tabagisme:effet du tabac
[TABAC] tabagisme:pathologie:pathologie neurologique:schizophrénieIndex. décimale : TA 4.1.1 Facteurs prédictifs du tabagisme (génétique inclus) Résumé : La prévalence du tabagisme dans des populations de schizophrènes est très élevé. Ce haut chiffre pose un problème de santé publique grave, par l'augmentation de la mortalité de ces patients. Les schizophrènes fumeurs semblent présenter plus de symptômes que les non fumeurs. Quand à l'arrêt du tabac des patchs de nicotine semblent importants pour augmenter les taux de succès. Un traitement par antipsychotiques atypiques augmente les réussites. Des groupes d'aide aux fumeurs spécialement conçus pour des patients schizophrènes impliquent qu'on tient conte de leur symptomatologie tout en fournissant de l'information, de la psycho éducation et de l'aide quand à la prévention de rechutes. Soutenir des patients schizophrènes à stopper le tabac est un travaille à long terme qui commence le plus tôt possible Ce texte est une revue de la littérature sur le problème du tabagisme chez des patients schizophrènes. En ligne : https://drive.google.com/file/d/0B_HRCWLoe3T-TUs1MzktamZmR2M/view?usp=sharing&re [...] Format de la ressource électronique : Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=188 Exemplaires (1)
Code-barres Cote Support Localisation Section Disponibilité TA 000989 TA 4.1.1 BOS A Mémoire/Thèse Bibliothèque FARES Tabac Consultation sur place
Exclu du prêtAucun avis, veuillez vous identifier pour ajouter le vôtre !
Titre : Varenicline as a smoking cessation aid in schizophrenia : effects on smoking behavior and reward sensitivity Type de document : texte imprimé Auteurs : Sunny J. Dutra, Auteur ; Luke E. Stoeckel, Auteur ; Sara V. Carlini, Auteur ; Diego A. Pizzagalli, Auteur Editeur : Springer Année de publication : 2012 Collection : Psychopharmacology num. 219 Importance : p.25-34 Langues : Anglais (eng) Catégories : [TABAC] sevrage tabagique:méthode de sevrage:méthode individuelle:approche pharmacologique:varénicline
[TABAC] tabagisme:pathologie:pathologie neurologique:schizophrénieIndex. décimale : TA 6.2.3.2 Autres produits Résumé : RATIONALE:
Smoking rates are up to five times higher in people with schizophrenia than in the general population, placing these individuals at high risk for smoking-related health problems. Varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, is a promising aid for smoking cessation in this population. To maximize treatment efficacy while minimizing risks, it is critical to identify reliable predictors of positive response to varenicline in smokers with schizophrenia.
OBJECTIVES:
Negative symptoms of schizophrenia are related to dysfunctions in the brain reward system, are associated with nicotine dependence, and may be improved by nicotine or nicotinic receptor agonists, suggesting that smoking cessation may be especially difficult for patients with substantial negative symptoms. The purpose of the study was to evaluate negative symptoms as predictors of response to varenicline.
METHODS:
Patients with schizophrenia (N = 53) completed a 12-week smoking cessation trial combining varenicline with cognitive behavioral therapy. Negative symptoms were assessed via the Scale for the Assessment of Negative Symptoms (Andreasen 1983). Outcomes included smoking abstinence as assessed by self-report and expired carbon monoxide. Change in performance on a probabilistic reward task was used as an index of change in reward sensitivity during treatment.
RESULTS:
At week 12, 32 participants met criteria for 14-day point-prevalence abstinence. Patients with lower baseline symptoms of affective flattening (more typical affect) were more likely to achieve smoking abstinence and demonstrated larger increases in reward sensitivity during treatment.
CONCLUSIONS:
These data suggest that affective flattening symptoms in smokers with schizophrenia may predict response to varenicline.En ligne : https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3267781/ Format de la ressource électronique : HTML Permalink : https://biblio.fares.be/opac_css/index.php?lvl=notice_display&id=8094 Aucun avis, veuillez vous identifier pour ajouter le vôtre !
